Related Experiment Video
Updated: Jun 3, 2026

09:34
Extraction and Characterization of Surfactants from Atmospheric Aerosols
Published on: April 21, 2017
QSPR modeling of nonionic surfactant cloud points: an update
Yueying Ren1, Baowei Zhao, Qing Chang
1School of Environmental and Municipal Engineering, Lanzhou Jiaotong University, Lanzhou, China. renry04.my265@yahoo.com.cn
Journal of Colloid and Interface Science
|March 23, 2011
Summary
Quantitative structure-property relationship (QSPR) models predict nonionic surfactant cloud points using selected molecular descriptors. These models offer reliable predictions, aiding in surfactant design and application.
Area of Science:
- Physical Chemistry
- Computational Chemistry
- Materials Science
Background:
- Nonionic surfactants exhibit cloud point behavior crucial for their applications.
- Predicting cloud points is essential for surfactant formulation and performance optimization.
- Quantitative Structure-Property Relationship (QSPR) modeling offers a computational approach to predict physical properties based on molecular structure.
Purpose of the Study:
- To develop robust Quantitative Structure-Property Relationship (QSPR) models for predicting the cloud points of nonionic surfactants.
- To identify key molecular descriptors that govern the cloud point behavior of these surfactants.
- To validate the developed models using rigorous internal and external datasets.
Main Methods:
- Utilized the CODESSA (Comprehensive Descriptor for Structural and Statistical Analysis) system to generate molecular descriptors.
- Employed a genetic algorithm (GA) for the selection of optimal descriptors.
- Developed and validated nonlinear models using Support Vector Machine (SVM) and Projection Pursuit Regression (PPR).
- Performed internal cross-validation (CV) and tested models on an independent external dataset.
Main Results:
- Identified four significant molecular descriptors correlating with nonionic surfactant cloud points.
- Developed validated QSPR models demonstrating good predictive accuracy for cloud points.
- Principal Component Analysis (PCA) was used to analyze descriptor interrelationships.
- External validation confirmed the generalization ability of the optimal QSPR model.
Conclusions:
- The developed QSPR models effectively predict the cloud points of nonionic surfactants.
- The identified descriptors provide insights into the structural factors influencing cloud point behavior.
- The validated models can serve as valuable tools for designing surfactants with desired cloud point properties.
Related Concept Videos
Surface Active Agents
Surfactants, named for their behavior at interfaces, positively adsorb at the interfaces of two phases, reducing interfacial tension. Their versatility as emulsifiers, detergents, and foaming agents stems from this ability. Surfactants, often termed amphiphiles, share the property of amphipathy, with molecules having both hydrophilic and hydrophobic portions. The hydrophilic part is called the head, and the hydrophobic part, including an elongated alkyl substituent, forms the tail.Surfactants...
Micelles
Micelle formation is an intricate process that hinges on the properties of amphiphilic or amphipathic molecules and the conditions of the system in which they are found. Amphiphilic molecules, which have both hydrophilic (water-attracting) and hydrophobic (water-repelling) parts, play a critical role in this process.In aqueous environments, these molecules arrange themselves such that their hydrophilic heads are turned towards the water phase, while their hydrophobic tails are oriented away...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).

